SCHEMBL11996551

SCHEMBL11996551

CCNc1nnc(-c2ccc(C)cc2F)o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
TP53 P04637 2/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
HSD17B10 Q99714 1/20 0.60
RXFP1 Q9HBX9 1/20 0.46
FLT1 P17948 1/20 0.39
KDR P35968 1/20 0.39
TDP1 Q9NUW8 2/20 0.37
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CHRNA7 P36544 3/20 0.36
KCNH2 Q12809 3/20 0.36
QPCT Q16769 1/20 0.36
CHRNA1 P02708 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CHRNB2 P17787 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11994400 0.82 KDM4E (0.46) NPC1RAB9ATP53KDM4EALDH1A1
SCHEMBL11996550 0.81 NPC1 (0.50) NPC1RAB9ATP53KDM4EALDH1A1
SCHEMBL16573949 0.77 NOTUM (0.45) NPC1RAB9ARXFP1MAPT
SCHEMBL11996756 0.75 RAB9A (1.00) NPC1RAB9ATP53KDM4EALDH1A1
SCHEMBL11994414 0.75 KDM4E (0.43) NPC1RAB9ATP53KDM4EALDH1A1
SCHEMBL15292166 0.75 KDM4E (0.44) NPC1RAB9ATP53KDM4EALDH1A1
SCHEMBL11996730 0.74 NPC1 (0.64) NPC1RAB9ATP53KDM4EALDH1A1
SCHEMBL12377800 0.74 KDM4E (0.68) NPC1RAB9ATP53KDM4EALDH1A1
SCHEMBL20387063 0.73 KDM4E (0.42) NPC1RAB9ATP53KDM4EALDH1A1
SCHEMBL12878761 0.73 KDM4E (0.42) NPC1RAB9ATP53KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2483263-B1 HETEROCYCLIC COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2018-07-18 EP disclosed
US-8658651-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-02-25 US disclosed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 US disclosed
US-20120214823-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME LLC 2012-08-23 US disclosed
US-20110038876-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS SCHERING CORPORATION 2011-02-17 US disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110038876-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS MAPK1, MAPK4, MAPK10 NPC1 2406/4885RAB9A 485/4885TP53 112/4885
US-20090118284-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPK10 NPC1 2087/4885RAB9A 360/4885TP53 135/4885
US-20120214823-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAPK10 NPC1 1625/4885RAB9A 212/4885TP53 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.